Loading live market data…

Corcept Therapeutics Incorporated

NASDAQ:CORT

$89.57 USD

-$0.9 (-0.99%)

Volume
928.9K
Average Volume
1.11M
Market Capitalization
$9.62B
P/E Ratio
199.04
Dividend Yield
0.00%
Price Target
$97.50
Year High
$95.11
Year Low
$28.66
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.86

Industry, Sector & symbol

Stock Exchange NASDAQ
CEO Joseph K. Belanoff
Industry Medical - Pharmaceuticals
Sector Healthcare
Current Symbol CORT
CUSIP 218352102
CIK 0001088856
Web https://www.corcept.com
Phone 650 327 3270
Currency USD
Employees 730
Country US

Liquidity

Debt-to-Equity Ratio 0.02
Payout Ratio 0.00
Current Ratio 2.86
Quick Ratio 2.77
Cash Ratio 0.73

Sales & Book Value

Annual Sales $761.41M
Price / Sales 12.50
Cash Flow 1.15
Price / Cash Flow 80.27
Price / Book 14.66

Price Target and Rating

Average Stock Price Forecast $97.50
High Stock Price Forecast $135.00
Low Stock Price Forecast $88.00
Forecast Upside/Downside -8.13%
Consensus Rating Neutral
Rating Score(0-5) 3
Research Coverage 26 Analysts

Profitability

EPS (Most Recent Fiscal Year) $0.82
Trailing P/E Ratio 199.04
PEG Ratio -3.08
P/E Growth -3.08
Net Income $99.65M
Net Margin 6.23%
Pretax Margin 1.58%
Return on Equity 7.50%
Return on Assets 5.88%

Financials Score

AltmanZ Score 33.73
Piotroski Score 5.00
Working Capital 276.85M
Total Assets 814.88M
Ebit 12.13M
Market Cap 9.22B
Total Liabilities 176.89M

Poll Results

About Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also inves ... tigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook

2026-07-12 15:06:35

The transaction realized $1.9 million in gross proceeds on July 7, 2026, at a weighted average price of $93.13 per share. The disposition was a cashless exercise of 20,000 options at a strike price of $21.65, followed by an immediate open-market sale.

Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors

2026-07-10 12:06:21

Corcept Therapeutics maintains a Buy rating, supported by robust revenue growth, pipeline progress, and strong management execution. Relacorilant's FDA approval in ovarian cancer and likely approval in Cushing's syndrome could drive CORT revenues above $3 billion annually by decade's end. 2026 revenue guidance of $950M–$1.05B reflects >30% YoY growth, with minimal impact expected from generic competition due to pipeline innovation.

Why Crinetics Stock Soared 99% This Week

2026-07-09 13:29:39

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.

Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm

2026-06-25 18:41:00

NEW YORK, June 25, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company's lead new product candidates, relacorilant, a medication being developed for multiple indications, including the treatment of hypercortisolism, or Cushing's syndrome.

Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome

2026-06-18 11:00:17

CORT resubmits relacorilant NDA for Cushing's syndrome, with updated analyses and data from multiple clinical studies supporting the filing.

Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm

2026-06-17 22:10:00

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders.

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome

2026-06-17 16:28:00

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing's syndrome.As requested by t.

Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm

2026-06-16 21:43:00

New York, New York--(Newsfile Corp. - June 16, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company's lead new product candidates, relacorilant, a medication being developed for multiple indications, including the treatment of hypercortisolism, or Cushing's syndrome.

Frequently Asked Questions

What is the current Corcept Therapeutics Incorporated (CORT) stock price?

Corcept Therapeutics Incorporated(NASDAQ:CORT) stock price is $89.57 in the last trading session. During the trading session, CORT stock reached the peak price of $95.11 while $28.66 was the lowest point it dropped to. The percentage change in CORT stock occurred in the recent session was --0.99% while the dollar amount for the price change in CORT stock was -$-0.9.

CORT's industry and sector of operation?

The NASDAQ listed CORT is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.

Who are the executives of CORT?

Sean Maduck | President of Endocrinology
Joseph K. Belanoff | Co-Founder, President, Chief Executive Officer & Director
Atabak Mokari | Chief Financial Officer & Treasurer
Amy Flood | Chief Human Resources & Communications Officer
Hazel Hunt | Chief Scientific Officer

How many employees does CORT have?

Number of CORT employees currently stands at 730. CORT operates from 149 Commonwealth Drive, Menlo Park, CA 94025, US.

Link for CORT official website?

Official Website of CORT is: https://www.corcept.com

How do I contact CORT?

CORT could be contacted at phone #650 327 3270 and can also be accessed through its website. CORT operates from 149 Commonwealth Drive, Menlo Park, CA 94025, US.

How many shares of CORT are traded daily?

The average number of CORT shares traded daily for last 3 months was 1.11M.

What is the market cap of CORT currently?

The market value of CORT currently stands at $9.62B with its latest stock price at $89.57